Y. Ma

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.

G. Mcmahon, Y. Ma, E. Carter, 2000, The Journal of investigative dermatology.

Chronically KIT-stimulated clonally-derived human mast cells show heterogeneity in different tissue microenvironments.

Y. Ma, B. Longley, V. Klump, 1997, The Journal of investigative dermatology.

Chymase cleavage of stem cell factor yields a bioactive, soluble product.

R. Halaban, D. Williams, Y. Ma, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Soluble cytokine receptors as carrier proteins: effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4.

R. Fernandez-Botran, Y. Ma, H. Hurst, 1996, The Journal of pharmacology and experimental therapeutics.

Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.

Y. Ma, X. Wang, B. Longley, 1999, The Journal of investigative dermatology.

Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy.

R. Fernandez-Botran, Y. Ma, P. Chilton, 1996, Advances in immunology.

Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.

Y. Ma, B. Longley, B J Longley, 2001, Leukemia research.

New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors.

G. Mcmahon, Y. Ma, E. Carter, 2000, Hematology/oncology clinics of North America.

Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

Y. Ma, A. Yayon, I. Vlodavsky, 1996, Proceedings of the National Academy of Sciences of the United States of America.